Full Breakdown
U.S. Launches RAPID Pathway for Accelerated Medicare Coverage of Medical Devices
4/24/2026, 3:33:46 AM
Overview of the RAPID Coverage Pathway
On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, designed to expedite Medicare coverage for certain breakthrough medical devices. This initiative aims to reduce the reimbursement timeline from over a year to approximately two months following FDA approval. The RAPID pathway specifically targets FDA-designated Class II and Class III devices, which often include higher-risk medical technologies.
Key Features of the RAPID Program
The RAPID pathway allows CMS and FDA to collaborate closely during the device review process, facilitating quicker Medicare coverage decisions. Under this program, CMS will issue a proposed national coverage determination on the same day an eligible device receives FDA marketing authorization, initiating a 30-day public comment period. Approximately 40 devices are expected to qualify for this accelerated coverage initially, with an additional 20 potentially eligible.
John Brooks, CMS Deputy Administrator, emphasized that the program will enhance transparency for device manufacturers, providing clear guidelines on the targets necessary for Medicare coverage. This initiative is seen as a significant advancement for major medical device companies like Medtronic and Johnson & Johnson, which have advocated for faster Medicare coverage.
Implications for Medical Device Manufacturers
The RAPID pathway is anticipated to foster innovation within the medical device industry by streamlining the reimbursement process. FDA Commissioner Marty Makary stated, “The American people deserve timely access to meaningful treatments without red tape or high costs.” The program is expected to improve access to new therapies for Medicare beneficiaries, addressing unmet clinical needs.
However, the effectiveness of the RAPID pathway will depend on its implementation. Scott Whitaker, CEO of AdvaMed, a medical device lobby group, noted the importance of accountability and management in realizing the full benefits of this initiative.
Criticism and Concerns
Despite the positive outlook, some stakeholders express skepticism regarding the RAPID pathway's potential impact. Concerns have been raised about the previous Transitional Coverage for Emerging Technologies (TCET) program, which limited coverage to only five devices per year. Critics argue that without meaningful timelines and effective management, the RAPID pathway may not significantly improve access to new technologies.
Official Statements
CMS Administrator Dr. Mehmet Oz remarked, “The RAPID coverage pathway brings our two agencies together earlier, cutting red tape for innovators, and helping beneficiaries access new, life-changing health technology faster.” This sentiment reflects the administration's commitment to enhancing the efficiency of the Medicare coverage process.
What's Next
The CMS plans to publish a procedural notice outlining the RAPID pathway in the Federal Register, initiating a 60-day public comment period. The agency will respond to public feedback in its final notice, indicating a commitment to refining the program based on stakeholder input.
In summary, the RAPID coverage pathway represents a significant shift in how Medicare addresses the reimbursement of breakthrough medical devices, potentially transforming the landscape for both manufacturers and patients.
